You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九州通(600998.SH)子公司藥品擬中標第三批國家藥品集中採購
格隆匯 08-20 19:08

格隆匯8月20日丨九州通(600998.SH)公佈,2020年8月20日,公司旗下工業板塊子公司北京京豐製藥集團有限公司(以下簡稱“北京京豐”)參加了第三批全國藥品集中採購的投標,北京京豐已通過國家藥品監督管理局仿製藥質量和療效一致性評價的鹽酸二甲雙胍片擬中標本次集中採購。

本次擬中標的產品鹽酸二甲雙胍片2019年銷售收入約為4,275萬元,約佔北京京豐2019年銷售收入的30%。由於公司主營業務主要為藥品、醫療器械等產品的線上、線下分銷業務,所以該產品銷售收入佔公司整體銷售收入的比重較小(約佔公司2019年營業收入的0.04%),預計不會對公司業績產生較大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account